

Prematurely ended - Statement

EudraCT Number:	2011-001474-25
Full title of the study:	A single-centre, single arm, open-label, exploratory trial of Interleukin-2 administered subcutaneously as neo-adjuvant treatment prior to sentinel lymph node biopsy (SLNB)/complete lymph node dissection (CLND) in subjects with stage III malignant melanoma.
Sponsor-Code:	SVM9122
Sponsor:	Charité – Universitätsmedizin Berlin
Principal Investigator/ Study Contact::	Dr. med. Felix Kiecker KLINIK FÜR DERMATOLOGIE, VENEROLOGIE UND ALLERGOLOGIE, Hauttumorzentrum, Charitéplatz 1, 10117 Berlin
Product:	Proleukin (Novartis)
Date of early termination:	2019/12/31
Statement:	Due to difficulties in recruitment and change of employer of the principal investigator in January 2020, no patient was enrolled in the study.